Givastomig is designed to simultaneously target CLDN18.2 and 4-1BB. CLDN18.2 is a tight junction protein that is typically ...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate ...
There’s a moment that never really left me. A small business owner from Limpopo had won a major fencing contract, tens of millions of rands’ worth of work. On paper, it was a breakthrough. In reality, ...
Nature's Formulas releases informational report outlining how Boostaro is described, ingredient research referenced in ...
Every Women’s Month, we talk about empowerment. We talk about inclusion. We talk about closing gaps. But perhaps the real ...
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of ...
A 2026 informational report covering how Red Boost describes its smooth muscle marketing claims, male sexual performance ingredient research context, pricing structure, and what consumers should know ...
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track ...
Automakers offer discounts exceeding ₹5 lakh on EVs, driven by fuel concerns and tax incentives, boosting sales before fiscal ...
The Brazilian Federal Prosecutor's Office (MPF), an independent body responsible for defending public interests, and state ...
In the open-label FIBROMET trial, metformin treatment was associated with reductions in bone marrow fibrosis and downregulation of key oncogenic signaling pathways in patients wit ...
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results